医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Promethera Biosciences: Announcement Regarding Business Activities in Japan

2019年10月31日 PM06:30
このエントリーをはてなブックマークに追加


 

MONT-SAINT-GUIBERT, Belgium & TOKYO

Promethera Biosciences SA (Group), a global innovator in cell-based medicines and liver diseases, announced the foundation of a new branch office in Tokyo, Promethera Biosciences Japan Branch Ltd on May, 2018. Establishing a branch office in Japan marks the starting point for building a strong presence of Promethera in Japan first, initially focusing on increased Business Development, Investor Relations activities and expansion of its business and products pipeline in Japan. This presence will also address the Asian markets as a second step.

As we develop such business activities, we are considering various options for further strengthening our presence in Japan. These options include future listing on the Tokyo Stock Exchange Market (whether or not using a Japanese Depositary Receipt (JDR scheme*) or another Asian stock exchange, and/or partnering with pharmaceuticals.

*for more information of the JDR scheme, please see
https://www.jpx.co.jp/english/equities/listing-on-tse/new/basic/05.html

About Promethera Biosciences:

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline, we develop antibody technologies such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert (Belgium), Durham (NC, USA), Tokyo (Japan) and Basel (Switzerland).

Promethera®, HepaStem®, H2stem®, are all registered trademarks of the PROMETHERA group.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191031005412/en/

CONTACT

Promethera Biosciences Japan Branch

Mutsuki Takano, Group CFO / Masumi Akahori, Senior IR Manager

info.japan@promethera.com

Tel: +81 (0)3-5843-6077

Web: www.promethera.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda to Divest TachoSil® to Corza Health for €350 Million
  • 新たな研究:ハンドドライヤーによる手の乾燥はペーパータオルと同じくらい衛生的
  • Body Fit Training PTY LTD Sues to Invalidate F45 Training PTY LTD’s U.S. Patents
  • Singapore and Apple Partner on National Health Initiative Using Apple Watch
  • 最新研究:干手机与用纸巾擦干双手一样卫生